"Toxys is a Dutch biotech company that provides innovative in vitro toxicity screening solutions to rapidly identify hazardous and potential carcinogenic properties of novel compounds during the early phases of product and drug development. We aim to bring information to our customers that is essential to make informed decisions on which compounds to progress in the drug/compound development pipeline, thereby contributing to the development of better medicines and products and to reduce animal testing."

"Cancer is a leading cause of death worldwide and this will only rise in ageing populations. Development of effective treatment, and identification of the patients that benefit from it remains a big challenge. High failure rates in clinical development, suboptimal treatment efficacy, unnecessary side effects, and difficulty to motivate associated cost for (novel) drug treatment while the burden for the health care system is widely debated.

VitroScan is dedicated to deliver predictive diagnostic tests. Both to improve patient selection for clinical trials, and to optimize drug treatment selection for cancer patients in the clinic."

"Hybridize Pharma is a pre-clinical stage biotech company that spun out from the Leiden University Medical Center in September 2019. We are a R&D-performing SME, creating value by developing RNA-based therapeutics specifically targeting viruses that become reactivated under immunosuppression. Hybridize Pharma has the ambition to become a global player in developing anti-viral therapies.

The concept of Hybridize Pharma was founded in July 2018 by Eric van der Veer, Anton Jan van Zonneveld and Jurriën Prins."

LUMC Association for PhD candidates (LAP) is a non-profit organization that represents the interests of all PhD candidates of Leiden University Medical Center. We are here to help you navigate this part of your career.